Pliant Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Net Income	-161.34	-123.32	-97.26	-41.53	-6.86	-35.15
Depreciation & Amortization	4.23	3.68	3.2	1.31	1.11	0.67
Share-Based Compensation	44.48	22.6	10.44	3.9	1.83	0.23
Other Operating Activities	-3.74	2.41	8.18	-0.94	-5.06	1.05
Operating Cash Flow	-116.36	-94.63	-75.44	-37.27	-2.75	-28.33
Capital Expenditures	-0.92	-1.76	-1.95	-1.53	-0.96	-2.32
Change in Investments	-126.09	-148.44	75.65	-209.33	-16.71	0
Other Investing Activities	-	-	-	-	-0.25	-
Investing Cash Flow	-127.01	-150.2	73.7	-210.87	-17.93	-2.32
Share Issuance / Repurchase	275.25	217.56	2.98	161.19	0.17	0.03
Debt Issued / Paid	0	9.85	0	0	0	0
Other Financing Activities	-0.85	-0.56	-0.46	52.02	45.37	87.32
Financing Cash Flow	274.41	226.85	2.53	213.21	45.54	87.35
Net Cash Flow	31.03	-17.98	0.78	-34.93	24.86	56.7
Free Cash Flow	-117.28	-96.39	-77.4	-38.8	-3.71	-30.65
Free Cash Flow Margin	-7422.91%	-995.26%	-1022.13%	-92.79%	-6.51%	-
Free Cash Flow Per Share	-2.00	-2.29	-2.16	-1.82	-2.29	-26.30

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).